Browse every published article, from the latest research to earlier analysis. Use the page numbers below to explore the complete archive.
A small number of events can produce unstable comparisons between treatment groups. A retrospective dental study examined 718 special-needs patients receiving propofol alone or propofol plus midazolam.
A short observation window may miss intermittent users. A Belgian older-adult analysis found a decline in standardized benzodiazepine receptor agonist use across survey years.
Clinical disappearance of movements does not necessarily establish electrographic seizure termination. A study compared midazolam and levetiracetam after usual neonatal seizure treatment failed.
Statistical significance does not by itself establish high-certainty evidence. A review found only two qualifying randomized comparisons of intravenous lorazepam and diazepam in adult status epilepticus.
A negative mechanistic assay narrows one concern without excluding every clinical hazard. Researchers expressed wild-type and mutant ryanodine receptors in cultured cells.
Repeated events and a withdrawal response can strengthen suspicion without establishing a population risk. An adult epilepsy report described recurrent low-temperature episodes after starting clobazam.
Patient attitudes provide a different kind of evidence from treatment efficacy data. A qualitative interview study explored maintenance approaches among people with high-dose benzodiazepine dependence.
Small group prevalence differences cannot identify which individual used a medicine nonmedically. Repeated Spanish school-survey data examined nonmedical benzodiazepine use among immigrant and native-born adolescents during 2006–2016.
A validated questionnaire is not automatically a diagnostic verdict in every population. A Brazilian study evaluated a Portuguese self-report dependence questionnaire in 179 chronic hypnotic users.
An adverse event during induction requires evaluation of all administered agents. A report described cardiorespiratory failure during anesthesia involving several drugs.
Response to an opioid antagonist does not test every substance in a mixed exposure. In an emergency-department toxicology investigation, illicit benzodiazepines were detected in twenty-one suspected opioid-overdose patients.
An antiemetic endpoint and a respiratory endpoint answer different questions. A laparoscopic-cholecystectomy study compared palonosetron alone with palonosetron plus midazolam during anesthetic induction.
A comparison allowing rescue fentanyl is not a test of never using fentanyl. In an elective cardiac-catheterization study, reported pain scores were similar for initial midazolam alone and midazolam plus fentanyl.
A pooled prescribing percentage can hide large differences in local practice. A multinational nursing-home study reported benzodiazepine or Z-drug use in more than a quarter of sampled residents, with substantial country differences.
Prescription-based prevalence measures healthcare transactions rather than exposure at a specific event. A Swiss insurance analysis estimated benzodiazepine and Z-drug prescribing prevalence and examined associations with healthcare admissions.
A health-status rating and a preference-weighted health index are related but distinct measures. A study of benzodiazepine users reported both a self-rated health score and an EQ health index.
Different follow-up outcomes can lead to different conclusions about the same withdrawal cohort. A retrospective hospital study associated phenobarbital treatment with shorter stays and lower all-cause thirty-day readmission and emergency-visit rates than lorazepam.
A favorable course in one complex operation does not establish comparative anesthetic safety. A cardiac-surgery case described remimazolam during induction and maintenance, including cardiopulmonary bypass.
Preventing an anesthetic-associated movement is a specific endpoint, not proof of comprehensive safety. In a three-group study, myoclonus after etomidate was less frequent with fentanyl–midazolam pretreatment than with either pretreatment alone.
A low parent-drug result need not capture the entire active exposure. A mexazolam review described metabolism to active products, including chloronordiazepam and chloroxazepam, and summarized anxiety-treatment studies.
Improvement after a drug is given does not isolate that drug’s contribution when toxin clearance is also occurring. A patient with lithium toxicity and persistent unconsciousness underwent dialysis.
A later anesthetic session may not reproduce the first session’s physiological baseline. A telemetric rat study repeated anesthetic regimens, including medetomidine–midazolam–fentanyl.
A lower sedative requirement can reflect preparation and anxiety management as well as drug potency. One hundred fifty bronchoscopy patients received either written consent information or additional multimedia information.
A comparison of premedications is not a comparison of isolated drug effects. A randomized study compared intramuscular dexmedetomidine with midazolam before surgery for vocal-fold lesions.
A memory-modifying effect can depend on prior exposure and experimental conditions. Researchers examined fear-memory reconsolidation after chronic ethanol exposure and withdrawal in rats.
Neurotransmitter concentrations and clinical sedation are different endpoints. A rat experiment used striatal microdialysis and chromatography after moschus, diazepam or combined exposure.
Respiratory deterioration may reflect both seizure physiology and treatment context. A report of Panayiotopoulos syndrome described a child with autonomic status epilepticus and respiratory arrest.
A drug’s chemical category does not settle every clinical similarity to benzodiazepines. A case report described escalating zolpidem use followed by seizures after interruption.
Faster recovery from a multidrug anesthetic does not identify which component was counteracted. A ninety-two-patient study compared aminophylline with saline at emergence.
A benzodiazepine-site imaging signal is not a direct test of sedative response. A PET study compared ten fragile X participants with ten controls using a flumazenil radiotracer.